Panobacumab (KBPA101) is a fully humanised monoclonal antibody targeting Pseudomonas aeruginosa, specifically targeting the O-polysaccharide (OPS) component of the bacterial outer membrane LPS. It is effective against certain drug-resistant strains of P. aeruginosa, reduces pulmonary inflammation, and enhances the clearance of bacteria from the lungs by neutrophils.

Panobacumab (0.0001-100 ng/mL, 2 hours) specifically mediates complement-dependent phagocytosis of Pseudomonas aeruginosa serotype O11 with an IC50 of 0.16 ng/mL.[1]

Methods: Panobacumab (0.005-0.4 mg/kg, intravenous injection, single dose) was used to treat a BALB/c mouse model of acute lung infection and its therapeutic efficacy was observed. Results: Panobacumab rapidly eliminated P. aeruginosa from the lungs and completely eliminated systemic P. aeruginosa from the spleen, whereas untreated mice still had viable bacteria 48 hours after infection and had milder lung pathology at 6 and 24 hours after infection. [1]